Genovis launches SialEXO®23 to enhance glycan research
Today Genovis expands its portfolio of glycan specific enzymes with the launch of SialEXO 23. A new member of the SialEXO family, SialEXO 23 is an enzyme for study of a specific type of sugar on biopharmaceuticals.
Most biopharmaceutical drugs are glycoproteins and the glycan composition is of interest to biopharma companies since it can impact the function and half-life of a particular therapeutic. The new product, SialEXO 23, is a specific sialidase for complete removal of α2-3 sialic acids and can be used to study the glycan composition on biopharmaceuticals.
“As the implications of glycosylation becomes increasingly more important for quality monitoring in the biopharma sector, we perceived a need for tools directed at sialylation analysis. SialEXO 23 provides our customers with easy way to probe sialylation of glycosylated biopharmaceuticals using their existing instrumentation like LC-MS.” says Fredrik Olsson, CEO, Genovis AB.
SialEXO 23 is the first new product launched by Genovis in 2019. The product will be presented at the annual conference of the American Society for Mass Spectrometry (ASMS) in Atlanta, Georgia which will be held June 2 - 6.
For more information about SialEXO® 23: https://www.genovis.com/products/enzymes-for-o-glycans/sialexo/
For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046 (0)46 -101233 fredrik.olsson@genovis.com
ABOUT GENOVIS
Genovis’ business concept is to apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs.
The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA). Genovis shares are listed on Nasdaq First North Stockholm and Erik Penser Bank is the Company’s Certified Adviser, certifiedadviser@penser.se, T: +46 (0)8-463 83 00.
This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.